Corresponding Author: Zhen Wang, PhD, Health Care Delivery Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (wang.zhen@mayo.edu).
Accepted for Publication: May 3, 2021.
Author Contributions: Drs VanderPluym and Wang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: VanderPluym, Halker Singh, Nayfeh, Farah, Saadi, Murad, Wang.
Acquisition, analysis, or interpretation of data: VanderPluym, Halker Singh, Urtecho, Morrow, Nayfeh, Torres Roldan, Hasan, Saadi, Shah, Abd-Rabu, Daraz, Prokop, Murad, Wang.
Drafting of the manuscript: VanderPluym, Halker Singh, Urtecho, Torres Roldan, Farah, Saadi, Abd-Rabu, Murad, Wang.
Critical revision of the manuscript for important intellectual content: VanderPluym, Halker Singh, Urtecho, Morrow, Nayfeh, Torres Roldan, Farah, Hasan, Saadi, Shah, Daraz, Prokop, Murad, Wang.
Statistical analysis: Halker Singh, Nayfeh, Saadi, Murad, Wang.
Obtained funding: Murad, Wang.
Administrative, technical, or material support: Halker Singh, Urtecho, Morrow, Nayfeh, Farah, Hasan, Saadi, Shah, Murad, Wang.
Supervision: VanderPluym, Halker Singh, Urtecho, Abd-Rabu, Wang.
Conflict of Interest Disclosures: Dr VanderPluym reports consulting for Teva and receiving a research grant from Amgen. Dr Halker Singh reports consulting for Teva and Impel. No other disclosures were reported.
Funding/Support: This project was funded under contract HHSA290201500013I task order 75Q80119F32007 from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS).
Role of the Funder/Sponsor: Mayo Clinic was awarded the contract by AHRQ to conduct this review through a competitive bidding process. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided technical assistance during the conduct of the full evidence report and provided comment on draft versions of the full evidence report. AHRQ did not directly participate in the literature search, design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The authors of this article are responsible for its content. Statement in the article does not necessarily represent the official views of or imply endorsement by AHRQ or HHS.
2.Vos
T , Lim
SS , Abbafati
C ,
et al Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
Lancet. 2020;396(10258):1204-1222. doi:
10.1016/S0140-6736(20)30925-9Google ScholarCrossref 10.Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality; 2014.
12.Bird
S , Derry
S , Moore
RA . Zolmitriptan for acute migraine attacks in adults.
Cochrane Database Syst Rev. 2014;2014(5):CD008616.
Google Scholar 14.Poolsup
N , Leelasangaluk
V , Jittangtrong
J , Rithlamlert
C , Ratanapantamanee
N , Khanthong
M . Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials.
J Clin Pharm Ther. 2005;30(6):521-532. doi:
10.1111/j.1365-2710.2005.00677.xPubMedGoogle ScholarCrossref 22.Croop
R , Goadsby
PJ , Stock
DA ,
et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet. 2019;394(10200):737-745. doi:
10.1016/S0140-6736(19)31606-XPubMedGoogle ScholarCrossref 24.Marcus
R , Goadsby
PJ , Dodick
D , Stock
D , Manos
G , Fischer
TZ . BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Cephalalgia. 2014;34(2):114-125. doi:
10.1177/0333102413500727PubMedGoogle ScholarCrossref 27.Lipton
RB , Dodick
DW , Ailani
J ,
et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial.
JAMA. 2019;322(19):1887-1898. doi:
10.1001/jama.2019.16711PubMedGoogle ScholarCrossref 28.Brandes
JL , Klise
S , Krege
JH ,
et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Cephalalgia. 2019;39(11):1343-1357. doi:
10.1177/0333102419864132PubMedGoogle ScholarCrossref 29.Färkkilä
M , Diener
H-C , Géraud
G ,
et al; COL MIG-202 Study Group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Lancet Neurol. 2012;11(5):405-413. doi:
10.1016/S1474-4422(12)70047-9PubMedGoogle ScholarCrossref 30.Ferrari
MD , Färkkilä
M , Reuter
U ,
et al; European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: a randomised proof-of-concept trial.
Cephalalgia. 2010;30(10):1170-1178. doi:
10.1177/0333102410375512PubMedGoogle ScholarCrossref 33.Brandes
JL , Klise
S , Krege
JH ,
et al Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study.
Cephalalgia Rep. 2020;3. doi:
10.1177/2515816320958176Google Scholar 36.Amiri
H , Ghodrati
N , Nikuyeh
M , Shams-Vahdati
S , Jalilzadeh-Binazar
M . Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: a randomized controlled trial study.
Turk J Emerg Med. 2017;17(2):61-64. doi:
10.1016/j.tjem.2016.12.004PubMedGoogle ScholarCrossref 39.Cete
Y , Dora
B , Ertan
C , Ozdemir
C , Oktay
C . A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs metoclopramide in the management of acute migraine attacks in the emergency department.
Cephalalgia. 2005;25(3):199-204. doi:
10.1111/j.1468-2982.2004.00840.xPubMedGoogle ScholarCrossref 41.Corbo
J , Esses
D , Bijur
PE , Iannaccone
R , Gallagher
EJ . Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache.
Ann Emerg Med. 2001;38(6):621-627. doi:
10.1067/mem.2001.119424PubMedGoogle ScholarCrossref 42.Dexter
SL , Graham
AN , Johnston
ES , Ratcliffe
DM , Wilkinson
MI , Rose
AJ . Double-blind controlled study of Paramax in the acute treatment of common and classical migraine.
Br J Clin Pract. 1985;39(10):388-392.
PubMedGoogle Scholar 43.Doğan
NO , Pekdemir
M , Yılmaz
S ,
et al. Intravenous metoclopramide in the treatment of acute migraines: a randomized, placebo-controlled trial.
Acta Neurol Scand. 2019;139(4):334-339. doi:
10.1111/ane.13063PubMedGoogle ScholarCrossref 48.Gaffigan
ME , Bruner
DI , Wason
C , Pritchard
A , Frumkin
K ; Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. A randomized controlled trial of intravenous haloperidol vs intravenous metoclopramide for acute migraine therapy in the emergency department.
J Emerg Med. 2015;49(3):326-334. doi:
10.1016/j.jemermed.2015.03.023PubMedGoogle ScholarCrossref 56.Shahrami
A , Assarzadegan
F , Hatamabadi
HR , Asgarzadeh
M , Sarehbandi
B , Asgarzadeh
S . Comparison of therapeutic effects of magnesium sulfate vs dexamethasone/metoclopramide on alleviating acute migraine headache.
J Emerg Med. 2015;48(1):69-76. doi:
10.1016/j.jemermed.2014.06.055PubMedGoogle ScholarCrossref 59.Tanen
DA , Miller
S , French
T , Riffenburgh
RH . Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Ann Emerg Med. 2003;41(6):847-853. doi:
10.1067/mem.2003.195PubMedGoogle ScholarCrossref 60.Kandil
M , Jaber
S , Desai
D ,
et al. MAGraine: Magnesium compared to conventional therapy for treatment of migraines.
Am J Emerg Med. 2021;39:28-33.
PubMedGoogle ScholarCrossref 61.Motamed
H , Mozafari
J , Porozan
S , Sasani
M . Magnesium sulfate and acute migraine: a randomized clinical trial.
Ann Clin Anal Med. 2020;11(5):369-373.
Google Scholar 66.Diener
H-C , Jansen
J-P , Reches
A , Pascual
J , Pitei
D , Steiner
TJ ; Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
Eur Neurol. 2002;47(2):99-107. doi:
10.1159/000047960PubMedGoogle ScholarCrossref 67.Friedman
AP , Di Serio
FJ , Hwang
DS . Symptomatic relief of migraine: multicenter comparison of Cafergot P-B, Cafergot, and placebo.
Clin Ther. 1989;11(1):170-182.
PubMedGoogle Scholar 79.Carleton
SC , Shesser
RF , Pietrzak
MP ,
et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
Ann Emerg Med. 1998;32(2):129-138. doi:
10.1016/S0196-0644(98)70126-XPubMedGoogle ScholarCrossref 80.Freitag
FG . The acute treatment of migraine with transnasal butorphanol (TNB).
Headache Q. 1993;4(suppl 3):22-28.
Google Scholar 90.Borhani Haghighi
A , Motazedian
S , Rezaii
R ,
et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study.
Int J Clin Pract. 2010;64(4):451-456. doi:
10.1111/j.1742-1241.2009.02215.xPubMedGoogle ScholarCrossref 91.Chou
DE , Shnayderman Yugrakh
M , Winegarner
D , Rowe
V , Kuruvilla
D , Schoenen
J . Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial.
Cephalalgia. 2019;39(1):3-14. doi:
10.1177/0333102418811573PubMedGoogle ScholarCrossref 92.Farahmand
S , Shafazand
S , Alinia
E , Bagheri-Hariri
S , Baratloo
A . Pain management using acupuncture method in migraine headache patients: a single blinded randomized clinical trial.
Anesth Pain Med. 2018;8(6):e81688. doi:
10.5812/aapm.81688PubMedGoogle Scholar 94.Korucu
O , Dagar
S , Çorbacioglu
SK , Emektar
E , Cevik
Y . The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments.
Acta Neurol Scand. 2018;138(3):212-218. doi:
10.1111/ane.12952PubMedGoogle ScholarCrossref 96.Lipton
RB , Dodick
DW , Silberstein
SD ,
et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.
Lancet Neurol. 2010;9(4):373-380. doi:
10.1016/S1474-4422(10)70054-5PubMedGoogle ScholarCrossref 98.Niazi
M , Hashempur
MH , Taghizadeh
M , Heydari
M , Shariat
A . Efficacy of topical rose (
Rosa damascena Mill.) oil for migraine headache: a randomized double-blinded placebo-controlled cross-over trial.
Complement Ther Med. 2017;34:35-41. doi:
10.1016/j.ctim.2017.07.009PubMedGoogle ScholarCrossref 99.Sasannejad
P , Saeedi
M , Shoeibi
A , Gorji
A , Abbasi
M , Foroughipour
M . Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial.
Eur Neurol. 2012;67(5):288-291. doi:
10.1159/000335249PubMedGoogle ScholarCrossref 104.Yarnitsky
D , Dodick
DW , Grosberg
BM ,
et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial.
Headache. 2019;59(8):1240-1252. doi:
10.1111/head.13551PubMedGoogle ScholarCrossref 106.Zargaran
A , Borhani-Haghighi
A , Salehi-Marzijarani
M ,
et al. Evaluation of the effect of topical chamomile (
Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study.
Neurol Sci. 2018;39(8):1345-1353. doi:
10.1007/s10072-018-3415-1PubMedGoogle ScholarCrossref 107.Hokenek
NM , Erdogan
MO , Hokenek
UD , Algin
A , Tekyol
D , Seyhan
AU . Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: a randomize controlled trial.
Am J Emerg Med. 2021;39:80-85. doi:
10.1016/j.ajem.2020.01.024PubMedGoogle ScholarCrossref 108.Antal
A , Bischoff
R , Stephani
C ,
et al. Low intensity, transcranial, alternating current stimulation reduces migraine attack burden in a home application set-up: a double-blinded, randomized feasibility study.
Brain Sci. 2020;10(11):21. doi:
10.3390/brainsci10110888PubMedGoogle ScholarCrossref 109.Marmura
MJ , Silberstein
SD , Schwedt
TJ . The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies.
Headache. 2015;55(1):3-20. doi:
10.1111/head.12499PubMedGoogle ScholarCrossref 110.Lipton
RB , Reed
ML , Kurth
T , Fanning
KM , Buse
DC . Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study.
Headache. 2017;57(10):1507-1521. doi:
10.1111/head.13179PubMedGoogle ScholarCrossref 111.Buse
DC , Reed
ML , Fanning
KM , Kurth
T , Lipton
RB . Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study.
Headache. 2017;57(1):31-44. doi:
10.1111/head.12962PubMedGoogle ScholarCrossref 112.Pringsheim
T , Davenport
WJ , Marmura
MJ , Schwedt
TJ , Silberstein
S . How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine.
Headache. 2016;56(7):1194-1200. doi:
10.1111/head.12870PubMedGoogle ScholarCrossref 113.Shapiro
RE , Hochstetler
HM , Dennehy
EB ,
et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
J Headache Pain. 2019;20(1):90. doi:
10.1186/s10194-019-1044-6PubMedGoogle ScholarCrossref 114.Szkutnik-Fiedler
D . Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies.
Pharmaceutics. 2020;12(12):E1180. doi:
10.3390/pharmaceutics12121180PubMedGoogle Scholar 115.Pearlman
EM , Wilbraham
D , Dennehy
EB ,
et al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls.
Hum Psychopharmacol. 2020;35(5):e2732. doi:
10.1002/hup.2732PubMedGoogle Scholar 117.Lipton
RB , Schwedt
TJ , Friedman
BW ,
et al Demographics, headache characteristics, and other factors associated with opioid use in people with migraine: results from the CaMEO study.
Neurology. 2019;92:S59.006.
Google Scholar 118.Lipton
RB , Araujo
AB , Nicholson
RA ,
et al Patterns of diagnosis, consultation, and treatment of migraine in the US: results of the OVERCOME Study. Presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA.
119.Ashina
S , Foster
SA , Nicholson
RA ,
et al Opioid use among people with migraine: results of the OVERCOME study. Presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA.
121.Bonafede
M , Wilson
K , Xue
F . Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine.
Cephalalgia. 2019;39(9):1086-1098. doi:
10.1177/0333102419835465PubMedGoogle ScholarCrossref